Biomodels would like to announce the publication of an important manuscript in PNAS that explores the potential role of mast cell tryptase in the development and severity of Inflammatory Bowel Disease (including Crohn’s Disease and Ulcerative Colitis). This manuscript was … Continue reading →

Skills in providing efficacy models combined with GLP toxicology know-how will provide clients with seamless development services Evreux, France and Watertown, MA, USA, December 16, 2010 – CIT, the preclinical drug safety CRO based outside Paris, and Biomodels, the Boston-based … Continue reading →

Stockholm, Sweden and Watertown, MA, USA – May 11, 2010 – Swedish Orphan Biovitrum (STO: BVT) and Biomodels LLC today announced a research agreement, under which Biomodels will explore the possibility of developing a clinically applicable screening platform that will … Continue reading →

Research Opens Door for Developing New Treatments Boston, MA (November 16, 2009) — Scientists at Biomodels have successfully developed the first model that accurately duplicates human cancer treatment-related fatigue (CTRF). The new model shows, that as in human cancer patients, … Continue reading →

Medical researchers will report findings (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration. The discovery by scientists at Biomodels, a preclinical drug research organization, and Lubris, a Massachusetts-based startup company, could … Continue reading →

Collaboration with Biomodels facilitates development of novel drug product. BURLINGTON, MA (Sept. 16) Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I … Continue reading →

ActoGeniX taps Biomodels CRO expertise in $1 billion market for cancer support care to relieve side effects of cancer treatments WATERTOWN, Mass., June 22 /PRNewswire/ — Biomodels LLC, a preclinical research organization specializing in cancer support care, today announced that … Continue reading →

MOUNTAIN VIEW, Calif.–(Business Wire)– Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop … Continue reading →

Biomodels has just completed the commissioning of new laboratory space combined and bought online new diagnostic imaging capabilities as well as new clinical diagnostic equipment. The new space increases Biomodels total capacity by 150%, and will increase Biomodels ability to … Continue reading →

Revised February 2008 Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition … Continue reading →